Balamuthia: Profounda receives Orphan Drug Designation to use miltefosine for treatment
by News Desk from Outbreak News Today on (#2V6FY)
Orlando-based specialty pharmaceutical company, Profounda announced it has received the US Food and Drug Administration's Orphan Drug Designation for the use of Impavido (miltefosine) to treat Granulomatous Amebic Encephalitis (GAE) caused by the free-living amoeba, Balamuthia . The Balamuthia amoeba is one cause of GAE. The amoeba is thought to enter the body when soil or ["]
The post Balamuthia: Profounda receives Orphan Drug Designation to use miltefosine for treatment appeared first on Outbreak News Today.